Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Prognosis and Treatment
www.UptoDate.com Mar, Wall, M. & Lee, A.G., 2022
Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Pseudotumor Cerebri
Adams & Victors Principles of Neurology, Chp 30, pg 628, Ropper, A.H.,et al, 2014
Update on the Pathophysiology and Management of Idiopathic Intracranial Hypertension
JNNP 83:488-494, Biousse,V.,et al, 2012
Diagnosis and New Treatment in Muscle Channelopathies
JNNP 80:360-365, Meola,G.,et al, 2009
Primary Episodic Ataxias:Diagnosis, Pathogenesis and Treatment
Brain 130:2484-2493, Jen, J.C.,et al, 2007
Successful Treatment of Hypnic Headache Syndrome with Acetazolamide
Neurol 61:1157-1158, Sibon,I,et al, 2003
Acetazolamide Treatment for Migraine Aura Status
Neurol 55:1588-1589, Haan,J.,et al, 2000
The Role of Weight Loss and Acetazolamide in the Treatment of Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)
Ophthalmology 105:2313-2317, Johnson,L.N.,et al, 1998
Familial Migraine with Vertigo and Essential Tremor
Neurol 46:458-460, Baloh,R.W.,et al, 1996
Coexistence of Migraine and Idiopathic Intracranial Hypertension without Papilledema
Neurol 46:1226-1230, Mathew,N.T.,et al, 1996
Acetazolamide-Induced Nephrolithiasis:Implications for Treatment of Neuromuscular Disorders
Neurol 43:1105-1106, Tawil,R.,et al, 1993
Idiopathic Intracranial Hypertension:Report of Seven Cases
Am J Med 93:391-395, Jain,N.&Rosner,F., 1992
The Effect of Acetazolamide on Essential Tremor:An Open-Label Trial
Neurol 42:1394-1395, Busenbark,K.,et al, 1992
Acetazolamide-Responsive Vestibulocerebellar Syndrome:Clinical & Oculographic Features
Neurol 41:429-433, Baloh,R.W.&Winder,A., 1991
Chronic Acetazolamide Monotherapy in the Treatment of Juvenile Myoclonic Epilepsy
Neurol 40:1677-1681, Resor,S.R.&Resor,L.D., 1990
The Rational Management of Idiopathic Intracranial Hypertension
Arch Neurol 46:1049-1051, Corbett,J.J.&Thompson,H.S., 1989
Paroxysmal Cerebellar Ataxia
Aust NZ J Med 19:113-117, Feeney,G.F.&Boyle,R.S., 1989
Acetazolamide-Responsive Myotonia Congenita
Neurol 37:488-491, Trudell,R.G.,et al, 1987
Acetazolamide-Responsive Episodic Ataxia Syndrome
Neurol 33:1212-1214, Zasorin,N.L.,et al, 1983
Central Sleep Apnea, Improvement With Acetazolamide Therapy
Arch Int Med 142:1816-1819, White,D.P.,et al, 1982
Acute Effects of Acetazolamide in Hyperkalemic Periodic Paralysis
Neurol 31:725-729, Riggs,J.E.,et al, 1981
Acetazolamide-Induced Improvement in Hydro-cephalus
Arch Neurol 37:376, Donat,J.F., 1980
Familial Periodic Ataxia
Arch Neurol 36:568-569, Donat,J.R.,et al, 1979
Hereditary Paroxysmal Ataxia:Response to Acetazolamide
Neurol 28:1259-1264, Griggs,R.C.,et al, 1978
Effects of Acetazolamide on Myotonia
Ann Neurol 3:531, Griggs,R.C.,et al, 1978
A Syndrome of Early Recognition of Occult Hydrocephalus & Cerebral Atrophy
Quart J Med 183:365, Botez,M.I.,et al, 1977
Hypokalemic Periodic Paralysis withArrhythmia
NEJM 286:253, Levitt,L.,et al, 1972
Effect of Chronic Anticonvulsant Therapy on Serum 25-Hydroxycalciferol Levels in Adults
NEJM 287:898, Hahn,T.,et al, 1972
Carbonic Anhydrase II Deficiency in 12 Families with Osteopetrosis with Renal Tubular Acidosis & Cerebral Calcification
NEJM 313:139-181, Sly,W.S.,et al, 1985
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Selimetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multcentre, International, Randomised Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study
Lancet 405:2217-2230, Chen,A.P.,et al, 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
NEJM 390:1745-1755, 1815, Connolly,S.J.,et al, 2024
Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Advances in Cerebral Venous Thrombosis
Stroke 55:2169-2172, deSousa,D.A. & Neto,L.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
Apixaban vs Aspirin in Patients with Cancer and Cryptogenic Stroke A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
JAMA Neurol 81:957-965, Navi,B.B.,et al, 2024